|
|
Chronic Pain Modulation of Mesolimbic Dopamine Signaling for Natural and Opiate Rewards |
| 1F31DA056200-01 |
|
NIDA |
2022 |
|
|
Increasing the health equity and population-level impact of a digital therapeutic for smokers with psychiatric illness |
| 1K02DA054304-01A1 |
|
NIDA |
2022 |
|
|
A Preconception Health Intervention to Reduce Substance Exposed Pregnancies among Incarcerated Women |
| 1K23DA053433-01A1 |
|
NIDA |
2022 |
|
|
Neurocognitive Impairments Resulting from Adolescent Prescription Opioid Use Disorder: Longitudinal Impact, Neural Mechanisms, and Comorbidities |
| 1K99DA056288-01 |
|
NIDA |
2022 |
|
|
Mechanisms of prenatal opioid exposure on brain and behavior |
| 1R01DA050871-01A1 |
|
NIDA |
2022 |
|
|
Impact of Medicare Part D opioid safety policies on disabled beneficiaries before and during the COVID-19 pandemic |
| 1R01DA055131-01 |
|
NIDA |
2022 |
|
|
Improving MOUD Access, Opioid-Related Outcomes and Equity Among Medicare Beneficiaries with Disability |
| 1R01DA057568-01 |
|
NIDA |
2022 |
|
|
Neurocognitive implications of cannabidiol (CBD) while aging with HIV |
| 1R03DA057146-01 |
|
NIDA |
2022 |
|
|
A telehealth tDCS approach to decrease cannabis use: Towards reducing multiple sclerosis disability in multiple sclerosis |
| 1R21DA055427-01 |
|
NIDA |
2022 |
|
|
Psychostimulants, Attention Deficit and Basal Ganglia Disorders |
| 1R21DA055980-01 |
|
NIDA |
2022 |